Synthesis and Cytotoxic Evaluation of Monocarbonyl Analogs of Curcumin as Potential Anti-Tumor Agents

Zheer Pan,1,2 Chengwei Chen,2 Yeli Zhou,2 Feng Xu,2 and Yaozeng Xu1*

1The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, People’s Republic of China
2Department of Orthopedic Surgery, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, People’s Republic of China

ABSTRACT A series of mono-carbonyl curcumin analogs with different substituents at the 4/4’-position of the phenyl group were synthesized and screened for in vitro cytotoxicity against a panel of human cancer cell lines using a methyl thiazolyl tetrazolium assay. Several of the curcumin analogs, especially B114, exhibited a wide-spectrum of anti-tumor properties in all tested cell lines, indicating their potential in as anti-cancer lead compounds. Further toxicity testing in the NRK-52E kidney cell line revealed that the analogs A111, A113, and B114 had comparable or higher safety than curcumin. These data suggested that the introduction of appropriate substituents in the 4/4’-positions could be a promising approach for curcumin-based drug design. Drug Dev Res 77: 43–49, 2016. © 2016 Wiley Periodicals, Inc.

Key words: monocarbonyl curcumin analogs; synthesis; anti-tumor activity

INTRODUCTION Curcumin is a polyphenolic natural product isolated from the rhizome of Curcuma longa Linn (Turmeric). It has multiple biological properties including antioxidant, anti-inflammatory, anti-infective, anti-cancer, and wound healing activities [Wilken et al., 2011; Prasad et al., 2014; Rainey et al., 2015]. In regard to its anti-cancer properties, curcumin can inhibit cell growth and induce apoptosis in a variety of cancer cell lines by modulating the activities of numerous transcription factors, growth regulators, adhesion molecules, apoptotic genes, and cellular signaling pathways [Chen et al., 2014; Wang et al., 2015]. Due to its anti-tumor properties and extremely low toxicity, curcumin is regarded as an ideal candidate for cancer therapy [Hatcher et al., 2008]. However, its clinical utility is limited by its chemical instability in vitro and poor metabolic properties in vivo [Pan et al., 1999; Rosemond et al., 2004]. This prompted the chemical modification and analog design of curcumin to identify more stable entities that may improve the in vivo metabolic profile and enhance anti-proliferative activity against cancer cells.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

*Correspondence to: Yaozeng Xu, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, People’s Republic of China. E-mail: xyzsz2001@126.com

Contract grant sponsor: Zhejiang Natural Science Funding; contract grant number: LY13H060007
Received 30 December 2015; Accepted 5 January 2016
Published online in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/ddr.21291

© 2016 The Authors Drug Development Research Published by Wiley Periodicals, Inc.
The instability and metabolic defects of curcumin may result from the high reactivity of the \( \beta \)-diketone group in the curcumin structure. Deletion of the \( \beta \)-diketone moiety increases the stability and improves the bioavailability of curcumin analogs in rat [Liang et al., 2009; Zhang et al., 2014]. Mono-carbonyl analogs of curcumin (MACs) with better pharmacokinetic properties and bioactivities than curcumin may represent novel therapeutic entities for the treatment of tumor and inflammatory diseases [Zhao et al., 2013].

Substituents on the 4/4'-position of curcumin may represent an important pharmacophore for biological activity [Ohtsu et al., 2002; Lin et al., 2006a,b; Quincoces Suarez et al., 2010]. The curcumin analog ASC-J9, which has a methoxy group at the 4/4'-position, had enhanced anti-androgenic activity and cytotoxicity against prostate cancer cell lines [Lin et al., 2006a,b; Shi et al., 2009].

In the present study, a variety of functional groups was used to replace the 4/4'-OH groups in MACs to develop potent and selective anticancer agents (Figure 1). Three series of compounds with different 5-carbon linkers (series A: cyclopentanone, series B: acetone and series C: cyclopentanone) and various substituents on the 4/4'-position of benzene rings were designed and synthesized. The cytotoxicity of these MACs was screened in the non-small cell lung cancer cell line H460 using a methyl thiazolyl tetrazolium (MTT) assay. Further, an anti-tumor evaluation in a panel of tumor cell lines showed that some analogs may possess improved anti-cancer activities as compared to curcumin.

METHODS AND MATERIALS

Chemistry

Melting points were determined on a SGW X-4 melting point apparatus and are uncorrected. Electrospray ionization-mass spectra in positive mode (ESI-MS) data were obtained with a Bruker Esquire 3000+ spectrometer. \(^1\)H-NMR spectra were recorded on Bruker 600 MHz instrument, and chemical shifts presented as parts per million with TMS as the internal reference.Solvents were distilled and dried by standard methods. Tetrahydrofuran (THF) was prepared by drying over 4Å molecular sieves overnight. Various alkyl halide and anhydride reagent were purchased from Aladdin and Sigma-Aldrich. Other chemicals were obtained from local suppliers and were used without further purification.

(2E,5E)-2,5-bis(4-hydroxy-3-methoxybenzylidene)cyclopentanone (4a), (1E,4E)-1,5-bis (4-hydroxy-3-methoxyphenyl)penta-1,4-dien-3-one (4b) and (2E,5E)-2,5-bis(4-hydroxy-3-methoxybenzylidene) cyclohexanone (4c) were prepared as described in the literature. [Liang et al., 2008].
temperature and the mixture extracted with ethyl acetate (50 mL×3) and the organic phase was washed with H2O, dried over anhydrous MgSO4 and the solvent evaporated to dryness. The crude product was purified by column chromatography eluting with petroleum ether and ethyl acetate to afford A110, A113, B110, B113, and B114.

A-110 - ((1E,1’E)-2-Oxocyclopentane-1,3-diylidene)bis(methanyllidendene)bis(2-methoxy-4,1-phenylene) dibenzoate

Yellow powder, 64.5% yield, mp 193.7–194.9°C.
\[ ^1H-\text{NMR } (\text{CDCl}_3) \delta: 3.163 (4H, s, CH₂–CH₂), 3.855 (6H, s, –OCH₃), 7.243 (2H, d, \text{J} = 9.0 \text{ Hz}, \text{Ar–H}^3), 7.25 (2H, s, –CH=–C), 7.282 (2H, d, \text{J} = 8.4 \text{ Hz}, \text{Ar–H}^6), 7.483–7.540 (4H, m, \text{Ar–H}^7), 7.609 (2H, s, Ar–H^5), 7.659 (2H, d, \text{J} = 7.2 \text{ Hz}, \text{Ar–H}^6), 8.212–8.236 (4H, m, \text{Ar–H}^2). \]

ESI-MS m/z: 489.1(M+H)⁺, calculated for C₃₅H₃₅O₇: 489.2.

A-111 - (2E,5E)-2,5-bis(4-(2-Hydroxyethoxy)-3-methoxybenzylidene)cylopentanone

Yellow powder, 56.2% yield, mp 234.0–235.7°C.
\[ ^1H-\text{NMR } (\text{CDCl}_3) \delta: 3.88 (6H, s, –OCH₂–CH₂), 7.02 (2H, d, \text{J} = 15.6 \text{ Hz}, \text{CO–CH}=), 7.23 (2H, d, Ar–H^3), 7.28 (2H, d, Ar–H^6), 7.53 (4H, t, \text{J} = 7.8 \text{ Hz}, \text{Ar–H}^5), 7.61 (2H, s, Ar–H^2), 7.65 (2H, t, \text{J} = 7.8 \text{ Hz}, \text{Ar–H}^6), 7.71 (2H, d, \text{J} = 15.6 \text{ Hz}, \text{Ar–CH}=), 8.23 (4H, d, Ar–H^2). \]

ESI-MS m/z: 535.0(M+H)⁺, calculated for C₂₃H₂₆O₇: 534.17.
TABLE 1. The Structures of Synthesized Compounds

| Compd. | n  | R                  | Compd. | N  | R                  | Compd. | n  | R                  |
|--------|----|--------------------|--------|----|--------------------|--------|----|--------------------|
| A110   | 2  | -acetophenone      | B110   | 0  | -acetophenone      | C111   | 3  | -CH₃CH₂OH          |
| A111   | 2  | -CH₃CH₂OH          | B111   | 0  | -CH₃CH₂OH          | C112   | 3  | -cyclopetane       |
| A112   | 2  | -cyclopetane       | B113   | 0  | -OCOCH₃            | C113   | 3  | -CH₂CH=CH₂         |
| A113   | 2  | -OCOCH₃            | B114   | 0  | -OCOCH₃            | C114   | 3  | -(CH₂)₂CH₃         |
| A115   | 2  | -CH₂=CH(CH₃)₂      | B115   | 0  | -CH₂=CH(CH₃)₂      | C116   | 3  | -(CH₂)₂CH₃         |
| A116   | 2  | -(CH₂)₂CH₃         | B116   | 0  | -(CH₂)₂CH₃         |        |    |                    |

Ar—H₂⁻ (2H, d, J = 15.6 Hz, Ar—CH=CH₂). ESI-MS m/z: 411.1 (M+H)⁺, calculated for C₃₂H₃₀O₅: 410.42.

**B-114 - (1(E,4E)-3-Oxopenta-1,4-diene-1,5-diyll)bis(2-methoxy-4,1-phenylene)dipropionate**

Yellow powder, 47.9% yield, mp 147.4–148.7°C. ¹H-NMR (CDCl₃) δ: 1.247–1.298 (6H, m, –CH₃(2x)), 2.614–2.652 (4H, m, –CH₂(2x)), 3.885 (6H, s, –OCH₃(2x)), 7.010 (2H, d, J = 15.6 Hz, CO—CH=CH₂), 7.078 (2H, d, J = 7.8 Hz, Ar—H³(2x)), 7.181 (2H, s, Ar—H²(2x)), 7.219 (2H, d, J = 7.8 Hz, Ar—H⁶(2x)), 7.810 (2H, d, J = 15.6 Hz, Ar—CH=CH₂). ESI-MS m/z: 438.9 (M+H)⁺, calculated for C₃₂H₃₀O₅: 438.17.

**B-115 - (1(E,4E)-1,5-bis(3-Methoxy-4-(3-methylbut-2-en-1-yl)oxy)phenyl)enta-1,4-dien-3-one**

Brick red powder, 58.6% yield, mp 93.9–95.2°C. ¹H-NMR (CDCl₃) δ: 1.755–1.780 (12H, m, –CH₃(4x)), 3.910 (6H, s, –OCH₃(2x)), 4.65 (4H, d, J = 6.6 Hz, –OCH₂(2x)), 5.520 (2H, t, –CH=CH₂), 6.9400 (2H, d, J = 8.4 Hz, Ar—H⁵(2x)), 7.02 (2H, d, J = 15.6 Hz, –CH=CH₂), 7.190 (2H, d, J = 8.4 Hz, Ar—H⁶(2x)), 7.27 (2H, s, Ar—H³(2x)), 7.71 (2H, d, J = 15.6 Hz, Ar—CH=CH₂). ESI-MS m/z: 463.1 (M+H)⁺, calculated for C₃₀H₂₄O₅: 462.24.

**C-111-(2E,6E)-2,6-bis(4-(2-Hydroxyethoxy)-3-methoxybenzylidene)cyclohexanone**

Yellow powder, 72.1% yield, mp 136.3–138.4°C. ¹H-NMR (CDCl₃) δ: 1.23–1.25 (2H, m, –CH₂(2x)), 2.93 (4H, d, J = 6.0 Hz, –CH₂(2x)), 3.81 (4H, t, –CH₂(2x)), 3.91 (6H, s, –OCH₃(2x)), 4.19 (4H, t, –OCH₃(2x)), 6.96 (2H, d, J = 7.8 Hz, Ar—H⁵(2x)), 7.20 (2H, d, J = 7.8 Hz, Ar—H⁶(2x)), 7.27 (2H, s, Ar—H²(2x)), 7.53 (2H, s, Ar—CH=CH₂). ESI-MS m/z: 455.2 (M+1)+, 477.1 (M+Na)+, calculated for C₂₉H₃₀O₅: 454.20.

**C-112-(2E,6E)-2,6-bis(4-(Cyclopentylxoxy)-3-methoxybenzylidene)cyclohexanone**

Yellow powder, 42.3% yield, mp 96.2–99.6°C. ¹H-NMR (CDCl₃) δ: 1.24–1.25 (2H, m, –CH₂(2x)), 1.57–1.59 (8H, m, –CH(3x)), 2.25 (8H, m, –CH(3x)), 2.93 (4H, t, –CH₂(2x)), 3.81 (2H, s, –CH₂(2x)).

![Graph](https://example.com/graph.png)

Fig. 3. Evaluation of the anti-proliferative activities of synthesized compounds. U2-OS cells were seeded in 96 well plate and incubated with different compounds with the concentration of 20 μM for 24 hours. Cell viability was assayed using an MTT assay. Data are expressed as fold change relative to control values (samples treated with DMSO alone), mean ± SEM. n ≥ 3. **P < 0.01 vs. DMSO group.
TABLE 2. Cytotoxic Test of A111, A113, B114 (IC50) Against Different Cancer Cell Lines

| Comp. cell line | IC50 (M) | A111 | A113 | B114 | Curcumin |
|-----------------|---------|------|------|------|---------|
| U2-OS           | 2.84    | 6.91 | 7.24 | 9.94 |
| OS-732          | 8.17    | 8.15 | 9.23 | 11.6 |
| A549            | >20     | >20  | 10.86| 13.97|
| HepG2           | >20     | >20  | 15.32| >20  |
| P815            | 3.26    | 2.60 | 0.84 | 10.33|
| PC 3            | 2.23    | >20  | 4.12 | 15   |
| Hela            | >20     | >20  | 3.23 | 17.5 |

—CH—), 3.91 (6H, s, —OCH3×2), 6.96 (2H, d, J = 7.8 Hz, Ar—H3×2), 7.20 (2H, d, J = 7.8 Hz, Ar—H5×2), 7.27 (2H, s, Ar—H2×2), 7.53 (2H, s, Ar—CH=×2). ESI-MS m/z: 503.2(M+1)+, calculated for C32H35O7: 502.27.

C-115 (2E,6E)-2,6-bis(3-Methoxy-4-((3-methylbut-2-en-1-yl)oxy)benzylidene)cyclohexanone

Brick red powder, 56.7% yield, mp 89.2–91.6°C. 1H-NMR (CDCl3): δ: 1.25-1.26 (2H, m, —CH2—), 2.93 (4H, t, —CH2—), 3.81 (4H, t, —CH2—×2), 3.91 (6H, s, —OCH3×2), 4.19 (4H, t, —OCH2×2), 6.96 (2H, d, J = 7.8 Hz, Ar—H5×2), 7.12 (2H, d, J = 15.6 Hz, —CH—×2), 7.20 (2H, d, J = 7.8 Hz, Ar—H6×2), 7.27 (2H, s, Ar—H2×2), 7.53 (2H, s, Ar—CH=×2). ESI-MS m/z: 505.2(M+1)+, 477.1(M+Na)+, calculated for C33H36O7: 545.20.

C-116 - (2E,6E)-2,6-bis(3-Methoxy-4-propoxybenzylidene)cyclohexanone

Yellow powder, 45.3% yield, mp 136.3–138.4°C. 1H-NMR (CDCl3): δ: 1.039 (6H, t, —CH3×2), 1.24–1.26 (2H, m, —CH2—), 1.81 (4H, m, —CH2—×2), 2.93 (4H, t, —CH2—), 3.89 (6H, s, —OCH3×2), 4.03 (4H, t, —OCH2×2), 6.91 (2H, d, J = 8.4 Hz, Ar—H3×2), 7.09 (2H, d, J = 8.4 Hz, Ar—H6×2), 7.27 (2H, s, Ar—H2×2), 7.74 (2H, s, Ar—CH=×2). ESI-MS m/z: 451.1(M+1)+, calculated for C28H34O5: 450.57.

Cell Culture and Methyl Thiazolyl Tetrazolium Assay

U2-OS, OS-732, HepG2, A549, P815, PC3, HeLa and normal renal NRK-52E cell lines were obtained from the American Type Culture Collection (ATCC, USA). All cell lines were cultured according to ATCC recommendations. Antiproliferative activity was determined using a MTT assay. Briefly, cells were seeded into 96-well plates at a density of 3000–5000 cells per well in 1640 medium, supplemented with 5% heat-inactivated serum, 100 U/ml penicillin, and 100 μg/mL streptomycin. Cells were maintained at 37°C in a humidified atmosphere containing 5% CO2. All experiments were carried out 24 h after cells were seeded. Tested compounds were dissolved in DMSO, and diluted with 1640 medium to the different concentrations of each compound. The tumor cells were incubated with test compounds for 72 h before the MTT assay. A fresh solution of MTT (5 mg/mL) prepared in NaCl solution (0.9%) was added to each single well of the 96-well plate. Plates were then incubated in a CO2 incubator for 3 h, cells dissolved with 150 μL DMSO, and then analyzed in a multi-well-plate reader at 490 nm. All results were representative from three or more independent experiments.

RESULTS AND DISCUSSION

Chemistry

The synthesis of the target MACs is shown in Figure 2. As the method reported in literature, the synthesis of compounds 4a, 4b and 4c started from the protection of commercially available vanillin with tetrahydrodihydropyran-2-yl to afford protected compound 1. 3-Methoxy-4-(tetrahydro-2H-pyran-2-yl)oxy)benzaldehyde 2 was obtained by reacting vanillin 1 with 3,4,2-H-dihydropyran in the presence of pyridinium p-toluenesulfonate. The aldol condensation of 2 with cyclopentanone or acetone afforded compound 3a, 3b and 3c, respectively. Hydroxylation analogs 4a, 4b and 4c were then obtained by deprotection with diluted hydrochloric acid as catalyst.

Fig. 4. Evaluation of the cytotoxicity of active compounds in NRK-52E cells. NRK-52E cells were seeded in 96 well plate and incubated with active compounds at a concentration of 20 μM for 24 hours. Cell viability was assessed using MTT assay. Data are expressed as fold change relative to control values (samples treated with DMSO alone), mean ± SEM. n ≥ 3. *P < 0.05 vs. DMSO group.
Finally, the intermediate compounds 4a, 4b and 4c were reacted with different alkyl halides in the presence of anhydrous potassium carbonate to yield the target compounds A111, A112, A115, A116, B111, B115, B116, C111, C112, C115, and C116. The 4’-OH of 4a, 4b, and 4c was also substituted by various alkyl esters through reacted with anhydride in the presence of TEA as catalyst. In this way, A110, A113, B110, B113, and B114 were obtained in good yield. The structures of all compounds are listed in Table 1.

Antiproliferative Activity
The in vitro anti-tumor activities of synthesized compounds were first evaluated in the human osteosarcoma cell line U2-OS using MTT assay at a concentration of 20 µM. The results presented in Figure 3 showed that these synthetic curcumin analogues exhibited different cytotoxic activities against U2-OS cells. Most compounds displayed lower activity compared with curcumin except compounds A111, A113, and B114. These showed more pronounced anti-tumor activity than curcumin in U2-OS cells. As curcumin has a wide-spectrum of anti-tumor properties, the IC50 values for A111, A113, and B114 were determined in other cancer cell lines. The antiproliferative activity of active compounds A111, A113, and B114 on human osteosarcoma OS-732, human hepatic cancer HepG2, lung cancer A549, prostate cancer PC-3, HeLa and mouse leukemia PS15 cell lines were evaluated in the MTT assay. The results shown in Table 2 suggest that B114 had wide-spectrum anti-proliferative properties, especially against PS15 (IC50 = 840 nM). A111 had selective, potent cytotoxicity against U2-OS (IC50 = 2.84 µM), OS-732 (IC50 = 8.17 µM), P815 (IC50 = 3.26 µM) and PC-3 (IC50 = 2.23 µM) cell lines, while A113 was only cytotoxic in U2-OS (IC50 = 7.24 µM) and OS-732 (IC50 = 9.23 µM) cells. Further studies were carried out to observe the preliminary safety of these compounds in the normal rat renal epithelial cell line NRK-52E by MTT assay. The results shown in Figure 4 indicated that the cell viability was reduced by approximately 50% when cells were incubated with 20 µM curcumin. However, growth of NRK-52E cells was only minimally affected by A111, while A113 and B114 had no inhibitory effect on renal cell growth suggesting that these three compounds have comparable or improved safety over curcumin at the same concentration.

CONCLUSIONS
In summary, we designed and synthesized a series of monocarbonyl curcumin analogs, some of which inhibited tumor cell proliferation. In particular, B114 had higher activity than curcumin against the tested tumor cell lines. Meanwhile, A111 showed potent cytokotoxicity against human osteosarcoma cell line U2-OS, prostate cancer cell line PC-3, human osteosarcoma cell line OS-732, and mouse mastocytoma cell line P815, implying their specific potential in the chemotherapy of cancer. Toxicity testing in vitro showed that A111, A113, and B114 did not affect growth of normal renal cells. This study presents a series of novel curcumin derivatives as potential anti-tumor candidates.

ACKNOWLEDGMENT
Financial support was provided by the Zhejiang Natural Science Funding (Grants LY13H060007).

REFERENCES
Chen B, Zhang Y, Wang Y, Rao J, Jiang X, Xu Z. 2014. Curcumin inhibits proliferation of breast cancer cells through Nrf2-mediated down-regulation of Fen1 expression. J Steroid Biochem Mol Biol 143:11–18.
Hatcher H, Planalp R, Cho J, Torti FM, Torti SV. 2008. Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci 65:1631–1652.
Liang G, Shao L, Wang Y, Zhao C, Chu Y, Xiao J, Zhao Y, Li X, Yang S. 2009. Exploration and synthesis of curcumin analogues with improved structural stability both in vitro and in vivo as cytotoxic agents. Bioorg Med Chem 17:2623–2631.
Liang G, Yang S, Jiang L, Zhao Y, Shao L, Xiao J, Ye F, Li Y, Li X. 2008. Synthesis and anti-bacterial properties of mono-carbonyl analogues of curcumin. Chem Pharm Bull 56(2):162–167.
Lin L, Shi Q, Su CY, Shih CC, Lee KH. 2006a. Antitumor agents 247. New 4-ethoxycarbonylethyl curcumin analogs as potential antiandrogenic agents. Bioorg Med Chem 14:2527–2534.
Lin L, Shi Q, Nyarko AK, Bastow KF, Wu CC, Su CY, Shih CY, Lee KH. 2006b. Antitumor agents. 250. Design and synthesis of new curcumin analogues as potential anti-prostate cancer agents. J Med Chem 49:3963–3972.
Ohtsu H, Xiao Z, Ishida J, Nagai M, Wang HK, Itokawa H, Su CY, Shih C, Chang T, Chang E, et al. 2002. Antitumor agents. 217. Curcumin analogues as novel androgen receptor antagonists with potential as anti-prostate cancer agents. J Med Chem 45:5037–5042.
Pan MH, Huang TM, Lin JK. 1999. Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab Dispos 27:486–494.
Prasad S, Gupta SC, Tyagi AK, Aggarwal BB. 2014. Curcumin, a component of golden spice: from bedside to bench and back. Biotechnol Adv 32:1053–1064.
Quinocaces Suarez JA, Rando DG, Santos RP, Goncalves CP, Ferreira E, de Carvalho JE, et al. 2010. New antitumor agents I: in vitro anticancer activity and in vivo acute toxicity of synthetic 1,5-bis(4-hydroxy-3-methoxyphenyl)-1,4-pentadien-3-one and derivatives. Bioorg Med Chem 18:6257–6261.
Rainey N, Motte L, Aggarwal BB, Petit PX 2015. Curcumin hormesis mediates a cross-talk between autophagy and cell death. Cell Death Dis 6:e2003.

Rosemond MJ, St John-Williams L, Yamaguchi T, Fujishita T, Walsh JS. 2004. Enzymology of a carbonyl reduction clearance pathway for the HIV integrase inhibitor, S-1360: role of human liver cytosolic aldo-keto reductases. Chem Biol Interact 147: 129–139.

Shi Q, Shih CC, Lee KH. 2009. Novel anti-prostate cancer curcumin analogues that enhance androgen receptor degradation activity. anti-cancer agents in medicinal chemistry 9:904–912.

Wang K, Fan H, Chen Q, Ma G, Zhu M, Zhang X, et al. 2015. Curcumin inhibits aerobic glycolysis and induces mitochondrial-mediated apoptosis through hexokinase II in human colorectal cancer cells in vitro. Anti-Cancer Drugs 26: 15–24.

Wilken R, Veena MS, Wang MB, Srivatsan ES. 2011. Curcumin: a review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma. Mol Cancer 10:12.

Zhang Y, Zhao C, He W, Wang Z, Fang Q, Xiao B, et al. 2014. Discovery and evaluation of asymmetrical monocarbonyl analogs of curcumin as anti-inflammatory agents. Drug Des Dev Ther 8:373–382.

Zhao C, Liu Z, Liang G 2013. Promising curcumin-based drug design: mono-carbonyl analogues of curcumin (MACs). Curr Pharm Des 19:2114–2135.